Intra-Cellular Therapies ...

131.64
0.04 (0.03%)
At close: Mar 21, 2025, 3:59 PM
131.64
0.00%
After-hours: Mar 21, 2025, 04:56 PM EDT
0.03%
Bid 131.22
Market Cap 14B
Revenue (ttm) 701.74M
Net Income (ttm) -76.99M
EPS (ttm) -0.72
PE Ratio (ttm) -182.83
Forward PE 686.6
Analyst Hold
Ask 131.75
Volume 1,411,406
Avg. Volume (20D) 3,128,949
Open 131.60
Previous Close 131.60
Day's Range 131.50 - 131.66
52-Week Range 64.09 - 131.67
Beta 0.70

About ITCI

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as ...

Sector Healthcare
IPO Date Jan 7, 2014
Employees 860
Stock Exchange NASDAQ
Ticker Symbol ITCI
Full Company Profile

Analyst Forecast

According to 13 analyst ratings, the average rating for ITCI stock is "Hold." The 12-month stock price forecast is $99, which is a decrease of -24.79% from the latest price.

Stock Forecasts

Next Earnings Release

Intra-Cellular Therapies Inc. is scheduled to release its earnings on May 6, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+34.07%
Intra-Cellular Therapies shares are trading higher... Unlock content with Pro Subscription
4 months ago
+11.36%
Intra-Cellular Therapies shares are trading higher after the company reported better-than-expected Q3 revenue results and raised its FY24 net product sales guidance. Also, Needham reiterated a Buy rating on the stock.